Skip to content
Translational Neuropharmacology Lab (Zanos Lab)

Translational Neuropharmacology Lab (Zanos Lab)

Our laboratory, based in Cyprus, employs molecular and systems neuroscience, behavioral pharmacology, as well as advanced computational methods to unravel the mysteries of brain diseases and identify targets for the development of novel and effective pharmacotherapies.

Menu
  • Home
  • News
  • Team Members
    • Lab Director
    • Current Team Members
    • Alumni
  • Research
  • Research Units
    • Translational Neuropharmacology Unit
    • Clinical Neuropsychopharmacology Unit
    • AI & Systems Bioinformatics Unit Cyprus
    • Genetic Epidemiology Unit
  • Facilities
  • Publications
  • Media
  • Join Us
  • Contact
  • More

Category: News

News

Cyprus Neuroscience Society now officially established: A historic milestone for Cyprus’ neuroscience community led by Dr. Zanos

No Comments
| News

The Translational Neuropharmacology Lab is proud to announce that the Cyprus Neuroscience Society (C.N.S.), founded and presided over by our Principal Investigator Dr. Panos Zanos, has reached another significant milestone with the launch of its official website: cnscyprus.com. This achievement builds upon Dr. Zanos’s vision to establish the first-ever neuroscience society in Cyprus (Registration Number: […]

Read More »

Dr. Zanos discusses innovative ketamine research at the American College of Greece (Deeree) faculty seminar

No Comments
| News

On Tuesday, April 8th, Dr. Zanos, Head of the Translational Neuropharmacology Lab, presented his groundbreaking research on ketamine’s antidepressant properties to faculty and students at Deree. The seminar, held in the Faculty Lounge, provided an intimate setting for in-depth discussion of novel therapeutic approaches to depression treatment. Dr. Zanos’s presentation explored the molecular pathways through […]

Read More »

New study by the Bioinformatics Unit of the Zanos lab suggests Metformin may offer better Alzheimer’s prevention potential in Diabetes patients compared with Semaglutide

No Comments
| News

The Zanos lab has recently published a preprint study examining the comparative effectiveness of diabetes medications in potentially reducing Alzheimer’s disease risk. The research was led by senior researchers Dr. Andrea Georgiou and Dr. Anna Onisiforou, key members of the Zanos laboratory team. The study, titled “Metformin Shows Greater Potential Than Semaglutide in Reducing Alzheimer’s […]

Read More »

Dr. Zanos presents our latest findings at University of Athens Neuroscience Seminar Series

No Comments
| News

Dr. Zanos, the Head of the Translational Neuropharmacology Lab, had the honor of presenting his research at the University of Athens as part of their Neuroscience Seminar Series. In his talk titled “Decoding ketamine: Neurobiological mechanisms underlying its rapid antidepressant efficacy,” Dr. Zanos shared his team’s findings on ketamine’s unique properties as an antidepressant. He […]

Read More »

New Publication: (2R,6R)-hydroxynorketamine prevents opioid abstinence-related negative affect and stress-induced reinstatement

No Comments
| News

The Zanos lab has just published a new study in the British Journal of Pharmacology demonstrating that the biologically-active metabolite of ketamine, (2R,6R)-hydroxynorketamine (HNK) shows potential for possibly addressing multiple aspects of opioid use disorder. In this comprehensive investigation, we established several mouse models that mimic some of the human endophenotypes of opioid dependence and […]

Read More »

Upcoming Seminar: “Decoding ketamine: Neurobiological mechanisms underlying its rapid antidepressant efficacy”

No Comments
| News

We are pleased to announce an upcoming seminar by Dr. Zanos, the Director of the Translational Neuropharmacology Lab at the Center for Applied Neuroscience & Department of Psychology of the University of Cyprus. In this seminar, Dr. Zanos will discuss how unlike traditional monoamine-based antidepressants that require weeks to exert effects, ketamine alleviates depression within […]

Read More »

Psychedelics as promising treatments for psychiatric disorders: Dr. Zanos’ article in Cyprus press

No Comments
| News

Dr. Panos Zanos, head of the Zanos Lab at the University of Cyprus, recently published an article in the Cyprus press, highlighting the therapeutic potential of psychedelics for treating psychiatric disorders. The article explores how substances like psilocybin, MDMA (ecstasy), and ketamine are emerging as innovative treatments for conditions such as depression and PTSD, particularly […]

Read More »

Dr. Andrea Georgiou delivers expert talk on smoking addiction biomarkers at KES College

No Comments
| News

We’re excited to announce that Dr. Andrea Georgiou, head of the Genetics Epidemiology Unit within the Zanos lab was invited to give a talk on her research on biomarkers associated with smoking addiction at KES College in Cyprus. The presentation focused on investigating biological indicators related to smoking dependence in the Cypriot population. Dr. Georgiou brings […]

Read More »

Dr. Zanos was invited to discuss groundbreaking ketamine clinical trial on Cyprus Broadcasting Corporation

No Comments
| News

We are pleased to announce that Dr. Zanos was recently invited to appear on the Cyprus Broadcasting Corporation (RIK) to discuss our laboratory’s groundbreaking clinical trial investigating ketamine as a treatment for opioid use disorder (OUD). This pioneering study—the first of its kind in Cyprus—is being conducted at the “GEFYRA” (BRIDGE) Substitute Substance Unit in […]

Read More »

New special issue led by our lab: Climate-Driven Effects on the Human Microbiome and Public Health

No Comments
| News

We’re excited to announce that our laboratory is leading a special issue in Microorganisms journal focusing on the intersection of climate change and the human microbiome. Dr. Zanos and Dr. Onisiforou are serving as Guest Editors for this initiative. Our special issue aims to explore how environmental changes affect human-associated microbial communities and their subsequent […]

Read More »

Posts pagination

Previous 1 … 5 6 7 … 13 Next

Recent Posts

  • Research spotlight: Unraveling the role of Eukaryotic Elongation Factor 2 Kinase in the antidepressant mechanism of (2R,6R)-hydroxynorketamine June 4, 2026
  • Research spotlight: Alexithymia and emotion regulation across smoking status groups May 26, 2026
  • New manuscript: The Immunosuppression Paradox in Multiple Sclerosis: Are We Fueling the Fire by Suppressing Immunity in an Epstein–Barr Virus–Linked Disease? March 12, 2026
  • New Preprint article – From Heatwaves to Brainwaves: Climate-Driven Microplastics Promote Epstein–Barr Virus Reactivation and Female-Biased Risk for Alzheimer’s Disease and Multiple Sclerosis February 24, 2026
  • New Publication – Linking Misophonia and Tinnitus: Common and Divergent Neurobiological Mechanisms January 29, 2026

Navigation

  • Home
  • News
  • Team Members
    • Lab Director
    • Current Team Members
    • Alumni
  • Research
  • Research Units
    • Translational Neuropharmacology Unit
    • Clinical Neuropsychopharmacology Unit
    • AI & Systems Bioinformatics Unit Cyprus
    • Genetic Epidemiology Unit
  • Facilities
  • Publications
  • Media
  • Join Us
  • Contact
  • More

Translational Neuropharmacology Lab (Zanos Lab) 2026 . Powered by WordPress